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Background: Obesity is a well established risk factor of colorectal cancer (CRC), but how body size influences risk of
colorectal cancer defined by key molecular alterations remains unclear. In this study, we investigated the
relationship between height, weight, body mass index (BMI), waist- and hip circumference, waist-hip ratio (WHR)
and risk of CRC according to expression of beta-catenin, cyclin D1, p53 and microsatellite instability status of the
tumours in men and women, respectively.
Methods: Immunohistochemical expression of beta-catenin, cyclin D1, p53 and MSI-screening status was assessed
in tissue microarrays with tumours from 584 cases of incident CRC in the Malmö Diet and Cancer Study. Six
anthropometric factors: height, weight, BMI, waist- and hip circumference, and WHR were categorized by quartiles
of baseline measurements and relative risks of CRC according to expression of beta-catenin, cyclin D1, p53 and MSI
status were calculated using multivariate Cox regression models.
Results: High height was associated with risk of cyclin D1 positive, and p53 negative CRC in women but not with
any investigative molecular subsets of CRC in men. High weight was associated with beta-catenin positive, cyclin
D1 positive, p53 negative and microsatellite stable (MSS) tumours in women, and with beta-catenin negative and
p53 positive tumours in men. Increased hip circumference was associated with beta-catenin positive, p53 negative
and MSS tumours in women and with beta-catenin negative, cyclin D1 positive, p53 positive and MSS tumours in
men. In women, waist circumference and WHR were not associated with any molecular subsets of CRC. In men,
both high WHR and high waist circumference were associated with beta-catenin positive, cyclin D1 positive and
p53 positive tumours. WHR was also associated with p53 negative CRC, and waist circumference with MSS tumours.
High BMI was associated with increased risk of beta-catenin positive and MSS CRC in women, and with
beta-catenin positive, cyclin D1 positive and p53 positive tumours in men.
Conclusions: Findings from this large prospective cohort study indicate sex-related differences in the relationship
between obesity and CRC risk according to key molecular characteristics, and provide further support of an
influence of lifestyle factors on different molecular pathways of colorectal carcinogenesis.* Correspondence: jenny.brandstedt@med.lu.se
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Colorectal cancer (CRC) is one of the most common
forms of human cancer worldwide with approximately 1
million new cases detected every year [1]. Numerous
epidemiological studies have examined the relationship
between body weight and risk of CRC, most of which
have demonstrated a positive association between a high
body weight and an increased risk of CRC, particularly
in men [2-4]. However, CRC is a largely heterogenous
disease in terms of its biological properties and accumu-
lating evidence suggest that aetiological factors influence
the carcinogenetic process differentially according to dif-
ferent molecular pathways [5-8].
Colorectal carcinogenesis can be regarded as a complex
process with multigene participation, mainly involving at
least three distinct pathogenetic pathways: chromosomal
instability (CIN), microsatellite instability (MSI) and CpG
island methylator phenotype (CIMP) [9,10]. The ‘suppres-
sor’ pathway involves loss of function of the tumour sup-
pressor genes APC (Adenomatosis Polyposis Coli gene),
DCC (Deleted in Colorectal Carcinoma gene), p53, and
activation of the proto-oncogene k-ras. This pathway ac-
counts for approximately 65-70% of sporadic CRC [11,12]
and for cancers associated with familial adenomatous
polyposis (FAP), constituting less than 1% of all CRC [13].
Beta-catenin is a membrane-associated protein with es-
sential functions in the regulation of cellular adhesion and
the major mediator of the Wnt-signaling pathway [14,15].
Inactivation of kinases in the APC-complex leads to accu-
mulation of cytoplasmic and nuclear beta-catenin, contrib-
uting to tumour progression [16-18]. Morikawa et al. have
recently shown that BMI is associated with a higher risk of
beta-catenin negative-, but not beta-catenin positive colo-
rectal cancer [19]. Cyclin D1 is activated by WNT/beta-
catenin signalling after mutation of the adenomatous
polyposis coli gene (APC) [20]. Cyclin D1 is an important
cell-cycle regulating protein and overexpression is seen in
about one third of CRC [21]. Although various studies
have linked the CCND1 G870A polymorphism to in-
creased CRC risk, the results remain controversial [22,23].
Inactivation of the p53 pathway by p53 mutations is one
of the key genetic steps in colorectal carcinogenesis and ap-
proximately 40-50% of tumours in the colon have alter-
ations in the p53 gene [24-26]. The p53 suppressor gene is
involved in numerous cellular processes, including induc-
tion of apoptosis and cell-cycle arrest, and p53 also plays an
important role in cellular energy metabolism [27-29]. It has
been shown that reduced nutrient or energy levels induce
p53 [30], and given the important role of diet and lifestyle
factors to the etiology of CRC, it can be hypothesized that
life style factors are associated with p53 mutations. Very
few previous studies have however addressed this question.
Slattery et al. have shown a positive relationship between
western style diet, but not obesity, and p53 mutations [31].The second pathway is initiated by germline mutations
in the mismatch repair (MMR) genes, e.g. MLH1, MSH2,
MSH6, and PMS2, or somatic tumour MLH1 promoter
methylation, leading to microsatellite instability (MSI).
MSI is detected in approximately 15% of sporadic CRC,
predominantly tumours located in the proximal colon,
and in almost all cancers from patients with hereditary
non-polyposis colon cancer (HNPCC), accounting for
3-5% of all CRC [32-34]. Previous data indicate an associ-
ation between obesity, MSS and risk of CRC [35].
Taken together, while it is well documented that body
size influences CRC risk, also with differences regarding
sex, location, and tumour stage [36], it remains unclear
how this association differs according to molecular tumour
phenotype.
The aim of this study was therefore to examine sex-
related differences in the relationship between anthropo-
metric factors and beta-catenin alterations, expression of
cyclin D1 and p53, and MSI screening status of incident
CRC in a large population based prospective cohort
study (n = 584).
Subjects and methods
Study group
Until end of follow-up 31 December 2008, 584 incident
cases of CRC had been registered in the prospective,
population-based cohort study Malmö Diet and Cancer
Study (MDCS) [37]. Between 1991–1996, a total number
of 28 098 individuals; 11 063 (39,4%) men and 17 035
(60,6%) women, between 44–74 years where enrolled
from a background population of 74 138. All partici-
pants completed the baseline examination, which in-
cluded a questionnaire, anthropometric measurements
and a dietary assessment. The questionnaire covered
questions on physical activity, use of tobacco and alco-
hol, heredity, socio-economic factors, education, occupa-
tion, previous and current disease and current medication.
In addition, blood samples were collected and stored
in −80°C. Follow up is performed annually by record-
linkage to national registries for cancer and cause of death.
Cases were identified from the Swedish Cancer Registry up
until 31 December 2007, and from The Southern Swedish
Regional Tumour Registry for the period of 1 January to
31 December 2008. All tumours with available slides or
paraffin blocks were histopathologically re-evaluated by a
senior pathologist (KJ) on haematoxylin and eosin-stained
slides. Histopathological, clinical and treatment data were
obtained from the clinical and/or pathology records. Infor-
mation on vital status and cause of death was obtained
from the Swedish Cause of Death Registry up until 31
December 2009. Patient and tumour characteristics of the
cohort, including specified location of colonic tumours,
have been described in detail previously [38-40]. Ethical
permissions for the MDCS (Ref. 51/90), and the present
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Anthropometric measurements
At baseline examination, weight, (multiples of 0.1 kg) and
height (to the nearest 0.005 m) were measured by a
trained nurse, and body mass index (BMI) was calculated
as kg/m2. Waist circumference was measured at the mid-
point between the lower ribs and the iliac crest, and for
hip circumference the level of greatest lateral extension
was used. These measurements were estimated to the
nearest 0.01 m. The waist and hip circumferences of each
participant were used to calculate waist-hip ratio (WHR;
cm/cm) as an additional measure of fat distribution.
Tissue microarray (TMA) construction and
immunohistochemistry
Tumours with an insufficient amount of material were ex-
cluded, and a total number of 557 (89.0%) tumours were
suitable for TMA construction. In brief, two 1.0 mm cores
were taken from each tumour and mounted in a new
recipient block using a semi-automated arraying device
(TMArrayer, Pathology Devices, Westminster, MD, USA).
As demonstrated previously, there was no selection bias
regarding the distribution of clinicopathological character-
istics between the TMA cohort and the full cohort [39].
For immunohistochemical analysis, 4 μm TMA-sections
were automatically pre-treated using the PT-link system
(DAKO, Glostrup, Denmark) and then stained in an Auto-
stainer Plus (DAKO, Glostrup, Denmark). MSI screening
status was evaluated as previously described [41]. Immu-
nohistochemical stainings were evaluated as negative
when all tumour cells showed loss of nuclear staining. Sur-
rounding stromal cells and tumour infiltrating lympho-
cytes served as internal controls for each biopsy core. A
nuclear reaction of tumour cells was assessed as a positive
staining. MSI screening status was defined in accordance
with previous studies [41] whereby tumour samples lack-
ing nuclear staining of MLH1, PMS2, MSH2 or MSH6
were considered to have a positive MSI screening status.
Hereafter, tumours with a positive MSI screening status
are referred to as MSI and tumours with negative MSI
screening status are referred to as MSS.
Immunohistochemical staining of beta-catenin was
performed and evaluated as previously described [42],
whereby membranous staining was denoted as 0 (present)
or 1 (absent), cytoplasmic staining intensity as 0–2 and
nuclear staining intensity as 0–2. In this study, the ana-
lyses were limited to nuclear expression of beta-catenin.
Cyclin D1 expression was evaluated as previously de-
scribed [38] and p53 positivity was defined as > = 50%
tumour cells with strong nuclear staining intensity in ac-
cordance with previous studies [40]. All immunohisto-
chemical stainings were evaluated by two independentobservers (SW and KJ), who were blinded to clinical and
outcome data. Scoring differences were discussed in order
to reach consensus.
Statistical methods
Distribution of established and potential risk factors for
CRC was compared between CRC cases and the rest of
the study cohort (Table 1). Distribution of cytoplasmic
and nuclear beta-catenin expression, expression of p53
and cyclin D1, and MSI-status is also shown in Table 1.
Anthropometric measurements were divided into quar-
tiles. Separate quartiles were calculated for men and
women [36]. A Cox proportional hazards analysis was
used in order to compare risk of CRC between different
categories of anthropometric factors according to beta-
catenin over-expression, p53, and cyclin D1 expression
and MSI screening status according to gender and tumour
location, i.e. colon vs rectum. This yielded hazard ratios
(HR) with a 95% confidence interval. Follow-up time was
defined as time from baseline to diagnosis, death or end of
follow-up 31 December 2009. The proportional hazards
assumption was confirmed by a log, - log plot [43]. In the
multivariate Cox analysis potential confounders were
included, i.e. age (years), educational level (not com-
pleted elementary school/elementary school (6–8 years)/
“grundskola” (9–10 years)/“studentexamen” (10–12 years)/
one year after “studentexamen”/university degree), smok-
ing habits (yes regularly, yes occasionally, former smoker,
never smoker), and alcohol consumption (g/day) (Table 1).
A case-to-case analysis examined the heterogeneity be-
tween different tumour subgroups regarding their associ-
ation to anthropometrics using an unconditional logistic
regression model. Chi square test was applied for as-
sessment of the distribution of investigative factors ac-
cording to baseline characteristics. All statistical
analyses were conducted using SPSS version 20 and 21
(SPSS Inc., Chicago, IL, USA). Trend was calculated as
linear trend over quartiles. A two-tailed p-value less
than 0.05 was regarded as statistically significant.
Results
Distribution of risk factors in cases and rest of cohort
As shown in Table 1, CRC cases were slightly older
(p <0.001 for both men and women), of higher weight
(p = 0.014 for men and p = 0.008 for women), had a higher
BMI (p = <0.001 for men and p = 0.001 for women), a
higher waist circumference (p < 0.001 for both men and
women), and a higher hip circumference (p < 0.001 for
men and p = 0.001 for women) and a higher WHR in men
(p = 0.021), than the rest of cohort. Among women, cases
had a higher level of education (p = 0.009), and had a
lower intake of alcohol (p = 0.002) than the rest of cohort.
There was a significant association between beta-catenin
positive tumours and level of education (p = 0.019), a
































Sex <0.001 0.863 0.226 0.722 0.057
Male (%) 10783 (39.2) 280 (47.9) 145 (47.7) 91 (46.9) 185 (46.2) 52 (53.1) 112 (46.5) 124 (48.1) 26
(36.6)
203 (48.8)







Age at baseline (years) 58.0 61.8 61.9 62.0 62.3 60.2 61.5 62.3 64.4 61.5
Male 59.2 61.7 <0.001 61.5 62.1 0.430 61.9 60.5 0.204 61.2 62.0 0.452 64.6 61.2 0.029
Female 57.3 62.1 <0.001 62.5 61.7 0.638 62.7 59.7 0.001 61.7 62.6 0.252 64.3 61.7 0.024
Smoking male (% ) 0.104 0.749 0.371 0.199 0.793
Regularly 2572 (25.5) 53 (18.9) 25 (17.2) 17 (18.7) 35 (18.9) 8 (15.4) 17 (15.2) 24 (19.2) 5 (19.2) 38 (18.5)
Occasionally 520 (4.8) 12 (4.3) 5 (3.4) 3 (3.3) 8 (4.3) 0 5 (4.4) 3 (2.4) 1 (3.89 7 (3.4)
Former smoker 4635 (43.0) 145 (51.7) 80 (55.2) 44 (48.4) 94 (51.4) 31 (59.6) 66 (58.9) 60 (48.0) 11
(42.3)
107 (52.2)
Never smoker 3046 (28.3) 70 (25.0) 35 (24.1) 27 (29.7) 48 (25.9) 13 (25.0) 24 (21.4) 38 (30.4) 9 (34.6) 53 (25.9)
Smoking female (%) 0.652 0.592 0.972 0.009 0.694
Regularly 4976 (29.8) 71 (23.4) 36 (22.6) 25 (24.3) 49 (22.8) 11 (23.9) 26 (20.2) 35 (26.1) 12
(26.7)
47 (22.1)
Occasionally 722 (4.3) 8 (2.6) 3 (1.9) 4 (3.9) 7 (3.2) 1 (2.2) 2 (1.6) 6 (4.5) 1 (2.2) 7 (3.3)
Former smoke 4637 (27.7) 87 (28.6) 41 (25.7) 30 (29.1) 57 (26.5) 13 (28.3) 27 (20.9) 43 (32.1) 9 (20.0) 59 (27.7)




Level of education male (%) 0.912 0.727 0.760 0.250 0.451
Not completed 85 (0.8) 2 (0.7) 1 (0.7) 0 1 (0.5) 0 1 (0.9) 0 0 1 (0.5)
6-8 years 4852 (45.1) 137 (48.9) 76 (52.4) 41 (45.1) 93 (50.3) 25 (48.1) 57 (50.9) 61 (48.8) 13
(50.0)
102 (49.8)
9-10 years 2113 (19.6) 55 (19.6) 28 (19.3) 21 (23.1) 35 (18.9) 14 (26.9) 24 (21.4) 25 (20.0) 4 (15.4) 44 (21.5)
10-12 years 1279 (11.9) 29 (10.4) 16 (11.0) 10 (11.0) 21 (11.3) 4 (7.7) 7 (6.3) 18 (14.4) 6 (23.1) 20 (9.8)
1 year university 998 (9.3) 19 (6.7) 9 (6.2) 5 (5.5) 12 (6.5) 2 (3.8) 9 (8.0) 5 (4.0) 1 (3.8) 13 (6.3)

















Table 1 Distribution of risk factors in cases and rest of cohort (Continued)
Level of education female (%) 0.009 0.019 0.796 0.496 0.316
Not completed 126 (0.8) 3 (1.0) 1 (0.6) 2 (1.9) 3 (1.4) 0 2 (1.6) 1 (0.7) 0 3 (1.4)




9-10 years 5086 (30.5) 75 (24.9) 27 (17.3) 35 (34.0) 52 (24.5) 12 (26.1) 26 (20.2) 38 (28.8) 13
(28.9)
50 (23.8)
10-12 years 1161 (7.0) 22 (7.3) 15 (9.6) 3 (2.9) 13 (6.1) 5 (10.9) 9 (7.0) 9 (6.8) 0 18 (8.6)
1 year university 1399 (8.4) 26 (8.6) 13 (8.3) 9 (8.7) 18 (8.5) 3 (6.5) 9 (7.8) 13 (9.8) 5 (11.1) 18 (8.6)
University degree 2496 (15.0) 25 (8.3) 12 (7.7) 6 (5.8) 15 (7.0) 4 (8.7) 9 (7.0) 10 (7.5) 2 (4.4) 16 (7.5)
Alcohol (g/day)
Male 15.5 15.7 0.868 17.4 14.3 0.070 16.2 15.0 0.648 16.9 0.731 12.6 16.6 0.331
Female 7.7 6.2 0.002 6.3 5.8 0.583 6.0 6.7 0.968 6.2 5.9 0.626 4.6 6.2 0.310
Height (cm)
Male 176.4 176.3 0.400 176.1 176.9 0.392 176.3 176.9 0.773 176.8 176.0 0.329 176.4 176.3 0.817
Female 163.6 163.3 0.220 162.8 163.6 0.179 163.4 162.6 0.394 162.2 164.2 0.006 163.1 163.3 0.620
Weight (kg)
Male 81.7 83.8 0.014 83.9 82.9 0.953 83.1 84.5 0.457 84.6 82.8 0.250 86.2 82.8 0.433
Female 68.0 70.0 0.008 70.9 68.3 0.112 70.4 71.0 0.881 69.0 71.5 0.154 68.9 70.7 0.484
BMI (kg/m2)
Male 26.2 26.9 <0.001 27.0 26.5 0.481 26.7 27.1 0.562 27.0 26.7 0.591 27.5 26.6 0.258
Female 25.4 26.3 0.001 26.7 25.5 0.013 26.7 27.0 0.525 26.2 26.5 0.929 25.9 26.5 0.402
WHR (cm/cm)
Male 0.94 0.95 0.021 0.95 0.94 0.027 0.95 0.95 0.676 0.95 0.95 0.482 0.94 0.95 0.889
Female 0.80 0.80 0.490 0.80 0.80 0.779 0.79 0.81 0.098 0.80 0.79 0.338 0.79 0.80 0.779
Waist (cm)
Male 94.0 96.3 <0.001 96.6 94.9 0.424 95.6 96.8 0.575 96.9 95.4 0.427 96.6 95.5 0.586
Female 77.9 80.1 0.001 80.9 78.8 0.215 79.9 81.9 0.299 79.9 80.7 0.839 79.0 80.6 0.494
Hip (cm)
Male 99.4 101.2 <0.001 101.0 101.0 0.602 100.8 101.6 0.687 101.7 100.7 0.391 102.2 100.8 0.554
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0.027) among men. Cyclin D1 positive tumours were as-
sociated with higher age (p = 0.001) in women. Further-
more, p53 positive tumours were associated with height
(p = 0.009), more frequent among never-smokers in
women (p = 0.009), and MSS was associated with higher
age in both men (p = 0.029) and in women (p = 0.024).Hazard ratios of CRC risk defined by different tumour
characteristics in women
Associations of anthropometric factors with tumour
biological parameters in women are shown in Table 2
(height, weight, hip) and Table 3 (BMI, WHR, waist). In
women, a high height was associated with risk of cyclin D1
positive (ptrend =0.031), and p53 negative (ptrend =0.004)
CRC. The risk of p53 negative tumours was highest in
the top quartile of height (p for heterogeneity = 0.013).
A high weight was associated with beta-catenin positive
(ptrend =0.010), cyclinD1 positive (ptrend =0.019), p53
negative (p = 0.004) and MSS tumours (ptrend =0.008).
Increased hip circumference was associated with beta-
catenin positive (ptrend =0.014), p53 negative (ptrend =0.042)
and MSS tumours (ptrend =0.005), but waist circumference
and WHR were not associated with risk of any of the mo-
lecular subsets of CRC. A high BMI was associated with in-
creased risk of beta-catenin positive (ptrend =0.004), but not
beta-catenin negative tumours, with the highest risk in the
top quartile (p for heterogeneity = 0.048). High BMI was
also associated with risk of MSS tumours (ptrend =0.009).Hazard ratios of CRC risk defined by different tumour
characteristics in men
Associations of anthropometric factors with tumour bio-
logical parameters in men are shown in Table 4 (height,
weight, hip) and Table 5 (BMI, WHR, waist).
High height in men was not associated with increased
risk of any of the molecular subsets of CRC, but high
weight was associated with beta-catenin negative
(ptrend =0.048) and p 53 positive (ptrend =0.026) CRC. A
high hip circumference was associated with beta-catenin
negative (ptrend =0.036), cyclin D1 positive (ptrend =0.034),
p 53 positive (ptrend =0.009) and MSS (ptrend =0.038) tu-
mours. High BMI was associated with cyclin D1 positive
(ptrend =0.019) and p 53 positive (ptrend =0.023) tumours,
and borderline significantly associated with beta-catenin
positive CRC (ptrend =0.050). High WHR was associated
with beta-catenin positive, but not beta-catenin negative
CRC (ptrend =0.001), with the highest risk in the top
quartile (p for heterogeneity = 0.015). A high WHR was
also associated with cyclin D1 positive (ptrend =0.015),
p 53 positive (ptrend =0.033) and p53 negative tumours
(ptrend =0.048). High waist circumference was associated
with beta-catenin positive (ptrend =0.009), cyclin D1positive (ptrend =0.009), p 53 positive (ptrend =0.003),
and MSS (ptrend =0.012) tumours.
Discussion
In this large prospective cohort study, we present data
on associations between anthropometric factors and risk
of molecular subsets of CRC, i.e. beta-catenin overex-
pression, expression of cyclin D1 and p53, and MSI
screening status.
Positive MSI screening status has recently been demon-
strated to be an independent favourable prognostic factor
in the here studied cohort [40]. In the present study, no
significant associations were found between any of the an-
thropometric measurements and risk of MSI tumours.
One previous prospective study has investigated the rela-
tionship between anthropometric factors and risk of CRC
according to MSI status, demonstrating an association of
high BMI with MSS tumours but not with MSI tumours
[35]. These data are generally in agreement with previous
case control studies [8,44]. Slattery et al. found that MSI
tumours were more common in older people, in women
and in the proximal colon, and found a positive relation-
ship between smoking and MSI, and no association be-
tween MSI tumours and obesity [8]. In this study, we
found significant associations of high weight, BMI
and hip circumference with MSS tumours in women.
Among men, significant associations were found be-
tween increased waist- and hip ratio and hip circumfer-
ence and MSS tumours. These results are consistent
with previous data from Hughes et al. [35], and also
generally in agreement with the two previous case con-
trol studies from Slattery and Campbell [8,44].
Several anthropometric factors were significantly associ-
ated with risk of beta-catenin positive CRC in both sexes;
i.e. high weight, BMI and hip circumference in women,
and high WHR and waist circumference in men. Differen-
tial effects on beta-catenin overexpression, attributable to
the top quartiles, were seen for BMI in women and WHR
in men. No anthropometric factors were associated with
beta-catenin negative tumours in women, whereas in men,
high weight and hip circumference were associated with
betacatenin negative CRC. Accumulating evidence support
a role of WNT/beta-catenin signalling in adipogenesis,
obesity and metabolic disorders [45,46], as well as in car-
cinogenesis [14,15]. Considering the dual roles of beta-
catenin in both colorectal carcinogenesis and energy
metabolism, we investigated potential links between obes-
ity and beta-catenin alterations in CRC. One former study
by Morikawa et al. examined the associations of beta-
catenin expression and obesity with survival from CRC
[47], showing an improved cancer-specific survival in
obese patients with tumours displaying nuclear beta-
catenin localization. In non-obese patients, there were no
associations between beta-catenin status and survival.
Table 2 Hazard ratios of CRC risk defined by different tumour characteristics in relation to height, weight and hip
circumference in women
Tumour characteristics Quartiles Height Weight Hip
Number of cases Cases RR Cases RR Cases RR
Positive nuclear beta-catenin 1 31 1.00 22 1.00 19 1.00
2 56 1.34(0.86-2.08) 39 1.50(0.89-2.52) 38 1.41(0.81-2.46)
3 39 1.32(0.82-2.13) 46 2.04(1.22-3.41) 37 1.28(0.73-2.26)
4 32 1.17(0.70-1.96) 51 1.87(1.12-3.10) 64 1.93(1.14-3.26)
p trend 0.593 0.010 0.014
Negative nuclear beta-catenin 1 20 1.00 19 1.00 21 1.00
2 30 1.13(0.64-2.00) 32 1.46(0.82-2.57) 21 0.72(0.39-1.32)
3 26 1.33(0.74-2.40) 22 1.17(0.63-2.17) 30 1.03(0.58-1.81)
4 27 1.56(0.86-2.84) 30 1.31(0.73-2.33) 31 0.88(0.50-1.55)
p trend 0.113 0.599 0.985
CyclinD1 positive 1 39 1.00 35 1.00 34 1.00
2 70 1.36(0.92-2.02) 54 1.32(0.86-2.02) 45 0.92(0.59-1.44)
3 53 1.47(0.97-2.23) 56 1.57(1.03-2.41) 57 1.11(0.72-1.70)
4 52 1.62(1.05-2.49) 69 1.60(1.06-2.42) 78 1.28(0.85-1.93)
p trend 0.031 0.019 0.110
CyclinD1 negative 1 12 1.00 6 1.00 6 1.00
2 14 0.80(0.37-1.73) 12 1.70(0.63-4.54) 11 1.42(0.52-3.85)
3 12 0.89(0.39-1.99) 14 2.38(0.91-6.22) 11 1.49(0.55-4.07)
4 8 0.61(0.24-1.53) 14 1.96(0.75-5.12) 18 2.13(0.83-5.48)
p trend 0.365 0.155 0.103
p53 positive (>50%) 1 30 1.00 25 1.00 19 1.00
2 46 1.16(0.73-1.84) 32 1.07(0.63-1.80) 32 1.19(0.67-2.10)
3 32 1.10(0.67-1.83) 34 1.31(0.77-2.20) 34 1.19(0.67-2.10)
4 21 0.78(0.43-1.39) 38 1.21(0.72-2.00) 44 1.31(0.76-2.28)
p trend 0.431 0.370 0.364
P53 negative (<50%) 1 25 1.00 16 1.00 21 1.00
2 40 1.39(0.82-2.37) 35 1.92(1.06-3.47) 25 0.85(0.48-1.53)
3 33 1.64(0.94-2.84) 37 2.36(1.31-4.26) 35 1.18(0.68-2.04)
4 39 2.17(1.25-3.76)* 45 2.36(1.33-4.21) 52 1.47(0.87-2.47)
p trend 0.004 0.004 0.042
MSI 1 11 1.00 8 1.00 9 1.00
2 14 1.01(0.46-2.23) 12 1.35(0.55-3.13) 9 0.68(2.271.71)
3 9 0.96(0.39-2.33) 11 1.49(0.60-3.71) 13 0.9(0.40-2.21)
4 11 1.43(0.61-3.38) 14 1.49(0.62-3.59) 14 0.81(0.34-1.90)
p trend 0.477 0.387 0.864
MSS 1 41 1.00 30 1.00 27 1.00
2 67 1.20(0.81-1.78) 58 1.64(0.05-2.55) 50 1.33(0.83-2.13)
3 56 1.39(0.92-2.09) 55 1.79(1.14-2.80) 52 1.34(0.84-2.13)
4 48 1.28(0.83-1.97) 69 1.87(1.21-2.88) 83 1.85(1.18-2.88)
p trend 0.203 0.008 0.005
Adjusted for age, level of education, smoking habits and alcohol consumption.
*Heterogeneity analysis with p < 0.05.
Brändstedt et al. Journal of Translational Medicine 2013, 11:293 Page 7 of 13
http://www.translational-medicine.com/content/11/1/293
Table 3 Hazard ratios of CRC risk defined by different tumour characteristics in relation to BMI, WHR and waist
and hip circumference in women
Tumour characteristics Quartiles BMI WHR Waist
Number of cases Cases RR Cases RR Cases RR
Positive nuclear beta-catenin 1 20 1.00 43 1.00 23 1.00
2 40 1.73(1.00-2.97) 29 0.83(0.52-1.34) 33 0.97(0.57-1.67)
3 43 1.79(1.05-3.05) 40 0.92(0.59-1.43) 51 1.40(0.85-2.30)
4 55 2.25(1.33-3.80)* 46 1.20(0.79-1.84) 51 1.36(0.82-2.25)
p trend 0.004 0.366 0.097
Negative nuclear beta-catenin 1 22 1.00 24 1.00 16 1.00
2 29 1.20(0.69-2.09) 25 1.21(0.69-2.12) 25 1.16(0.62-2.18)
3 28 1.06(0.60-1.87) 32 1.31(0.77-2.22) 37 1.51(0.84-2.73)
4 24 0.89(0.49-1.61) 22 0.97(0.54-1.74) 25 1.00(0.53-1.90)
p trend 0.588 0.952 0.860
CyclinD1 positive 1 35 1.00 55 1.00 31 1.00
2 53 1.31(0.85-2.02) 48 1.07(0.72-1.58) 49 1.09(0.69-1.72)
3 61 1.42(0.94-2.17) 62 1.12(0.77-1.62) 75 1.51(0.99-2.31)
4 65 1.48(0.97-2.25) 49 0.98(0.66-1.45) 59 1.14(0.73-1.78)
p trend 0.076 0.997 0.357
CyclinD1 negative 1 7 1.00 10 1.00 8 1.00
2 12 1.64(0.64-4.20) 7 0.80(0.31-2.11) 7 0.69(0.25-1.90)
3 9 1.19(0.44-3.23) 12 1.18(0.51-2.74) 12 1.08(0.44-2.66)
4 18 2.46(1.00-6.02) 17 1.92(0.87-4.22) 19 1.81(0.78-4.21)
p trend 0.071 0.066 0.063
p53 positive (>50%) 1 19 1.00 30 1.00 21 1.00
2 33 1.51(0.85-2.67) 27 1.10(0.65-1.86) 27 0.89(0.50-1.59)
3 38 1.63(0.93-2.84) 35 1.20(0.73-1.96) 40 1.20(0.70-2.05)
4 39 1.65(0.94-2.89) 37 1.41(0.87-2.31) 41 1.23(0.72-2.10)
p trend 0.103 0.158 0.248
P53 negative(<50%) 1 23 1.00 35 1.00 18 1.00
2 33 1.29(0.75-2.21) 28 0.96(0.58-1.58) 29 1.16(0.64-2.09)
3 33 1.23(0.72-2.11) 39 1.08(0.68-1.71) 49 1.77(1.03-3.06)
4 44 1.61(0.96-2.71) 31 0.95(0.58-1.54) 37 1.28(0.72-2.27)
p trend 0.091 0.953 0.236
MSI 1 10 1.00 11 1.00 6 1.00
2 9 0.79(0.32-1.95) 10 1.08(0.46-2.55) 13 1.53(0.58-4.05)
3 14 1.09(0.48-2.48) 14 1.22(0.56-2.70) 16 1.59(0.62-4.10)
4 12 0.91(0.39-2.25) 10 0.96(0.41-2.27) 10 0.95(0.34-2.65)
p trend 0.972 0.971 0.765
MSS 1 31 1.00 57 1.00 33 1.00
2 56 1.60(1.03-2.50) 44 0.94(0.63-1.40) 43 0.92(0.58-1.46)
3 55 1.51(0.97-2.36) 55 0.96(0.66-1.40) 69 1.37(0.90-2.08)
4 70 1.90(1.23-2.93) 56 1.10(0.76-1.60) 67 1.31(0.85-2.00)
p trend 0.009 0.625 0.065
Adjusted for age, level of education, smoking habits and alcohol consumption.
*Heterogeneity analysis with p < 0.05.
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Table 4 Hazard ratios of CRC risk defined by different tumour characteristics in relation to height, weight and hip
circumference in men
Tumour characteristics Quartiles Height Weight Hip
Number of cases Cases RR Cases RR Cases RR
Positive nuclear beta-catenin 1 40 1.00 29 1.00 26 1.00
2 36 0.97(0.61-1.55) 42 1.41(0.86-2.29) 33 1.28(0.76-2.18)
3 33 0.71(0.44-1.14) 35 1.15(0.69-1.93) 45 1.55(0.93-2.57)
4 42 1.15(0.73-1.81) 45 1.53(0.94-2.49) 47 1.39(0.84-2.30)
p trend 0.877 0.180 0.182
Negative nuclear beta-catenin 1 14 1.00 19 1.00 17 1.00
2 26 2.13(1.09-4.16) 19 1.02(0.53-1.94) 11 0.65(0.30-1.40)
3 32 1.94(1.00-3.75) 26 1.31(0.71-2.43) 33 1.87(1.02-3.42)
4 27 1.90(0.96-3.79) 35 1.70(0.94-3.07) 38 1.46(0.79-2.70)
p trend 0.122 0.048 0.036
CyclinD1 positive 1 45 1.00 40 1.00 36 1.00
2 46 1.16(0.76-1.77) 49 1.23(0.80-1.89) 32 0.91(0.56-1.48)
3 53 1.02(0.67-1.54) 44 1.08(0.69-1.68) 61 1.57(1.02-2.41)
4 52 1.25(0.82-1.90) 63 1.57(1.04-2.39) 67 1.38(0.90-2.12)
p trend 0.442 0.058 0.034
CyclinD1 negative 1 10 1.00 8 1.00 7 1.00
2 15 1.48(0.66-3.34) 12 1.39(0.57-3.42) 12 1.65(0.65-4.21)
3 13 1.00(0.43-2.32) 17 1.85(0.79-4.34) 16 2.12(0.87-5.18)
4 17 1.52(0.68-3.43) 18 1.78(0.76-4.22) 20 1.90(0.78-4.62)
p trend 0.513 0.151 0.159
p53 positive (>50%) 1 22 1.00 20 1.00 15 1.00
2 32 1.64(0.93-2.90) 26 1.27(0.70-2.30) 22 1.48(0.76-2.90)
3 32 1.31(0.74-2.31) 33 1.42(0.79-2.54) 38 2.29(1.23-4.26)
4 33 1.65(0.93-2.92) 40 1.85(1.06-3.23) 44 2.12(1.14-3.92)
p trend 0.191 0.026 0.009
P53 negative (<50%) 1 32 1.00 27 1.00 27 1.00
2 30 1.02(0.62-1.70) 36 1.33(0.79-2.22) 22 0.82(0.46-1.46)
3 33 0.84(0.51-1.39) 27 1.06(0.61-1.83) 39 1.36(0.82-2.27)
4 36 1.13(0.68-1.87) 41 1.48(0.88-2.48) 43 1.15(0.69-1.91)
p trend 0.845 0.251 0.288
MSI 1 5 1.00 4 1.00 5 1.00
2 9 2.07(0.69-6.20) 7 1.76(0.51-6.05) 5 0.94(0.27-3.26)
3 5 0.98(0.28-3.42) 7 1.91(0.55-6.60) 6 1.06(0.32-3.51)
4 8 1.79(0.55-5.77) 9 2.36(0.70-7.96) 11 1.45(0.49-4.32)
p trend 0.630 0.176 0.431
MSS 1 48 1.00 46 1.00 39 1.00
2 51 1.16(0.77-1.74) 51 1.09(0.73-1.65) 39 1.03(0.65-1.61)
3 59 1.02(0.69-1.53) 52 1.07(0.71-1.62) 64 1.54(1.02-2.33)
4 58 1.25(0.83-1.87) 67 1.38(0.93-2.05) 74 1.40(0.93-2.11)
p trend 0.411 0.126 0.038
Adjusted for age, level of education, smoking habits and alcohol consumption.
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Table 5 Hazard ratios of CRC risk defined by different tumour characteristics in relation to BMI, WHR and waist
circumference in men
Tumour characteristics Quartiles BMI WHR Waist
Number of cases Cases HR Cases HR Cases HR
Positive nuclear beta-catenin 1 33 1.00 29 1.00 26 1.00
2 31 0.90(0.54-1.48) 28 1.21(0.71-2.08) 27 0.90(0.52-1.56)
3 37 0.97(0.60-1.59) 43 1.60(0.99-2.59) 47 1.36(0.84-2.23)
4 50 1.52(0.96-2.41) 51 2.14(1.34-3.42)* 51 1.66(1.02-2.69)
p trend 0.050 0.001 0.009
Negative nuclear beta-catenin 1 25 1.00 30 1.00 21 1.00
2 15 0.57(0.29-1.10) 18 0.78(0.43-1.45) 11 0.43(0.20-0.91)
3 21 0.72(0.39-1.33) 26 0.98(0.57-1.68) 33 1.21(0.69-2.12)
4 38 1.51(0.86-2.57) 25 0.96(0.54-1.69) 34 1.27(0.72-2.23)
p trend 0.074 0.993 0.076
CyclinD1 positive 1 47 1.00 45 1.00 39 1.00
2 33 0.69(0.44-1.09) 39 1.13(0.72-1.77) 29 0.62(0.38-1.02)
3 50 0.93(0.61-1.42) 54 1.33(0.89-2.00) 63 1.22(0.80-1.84)
4 66 1.46(0.99-2.16) 58 1.61(1.08-1.42) 65 1.40(0.93-2.10)
p trend 0.019 0.015 0.009
CyclinD1 negative 1 11 1.00 14 1.00 8 1.00
2 12 0.95(0.41-2.19) 6 0.48(0.17-1.32) 9 1.02(0.39-2.64)
3 10 0.78(0.33-1.86) 17 1.28(0.63-2.61) 17 1.64(0.70-3.84)
4 22 1.75(0.83-3.71) 18 1.32(0.63-2.72) 21 2.01(0.87-4.64)
p trend 0.146 0.211 0.046
p53 positive (>50%) 1 23 1.00 25 1.00 16 1.00
2 22 0.89(0.49-1.62) 24 1.18(0.66-2.12) 21 1.05(0.54-2.04)
3 32 1.17(0.67-2.04) 33 1.43(0.84-2.44) 41 1.85(1.02-3.33)
4 42 1.69(0.99-2.88) 37 1.72(1.02-2.91) 41 2.05(1.14-3.68)
p trend 0.023 0.033 0.003
P53 negative (<50%) 1 34 1.00 32 1.00 30 1.00
2 23 0.65(0.38-1.13) 22 0.91(0.52-1.59) 16 0.48(0.26-0.89)
3 28 0.73(0.43-1.24) 38 1.33(0.82-2.15) 40 1.05(0.64-1.71)
4 46 1.44(0.90-2.30) 39 1.52(0.93-2.47) 45 1.25(0.76-2.03)
p trend 0.084 0.048 0.070
MSI 1 5 1.00 6 1.00 5 1.00
2 5 0.98(0.28-3.42) 5 1.27(0.39-4.18) 4 0.73(0.20-2.72)
3 6 0.95(0.27-3.34) 9 1.82(0.64-5.15) 9 1.58(0.53-4.75)
4 11 2.47(0.84-7.26) 7 1.52(0.48-4.80) 9 1.50(0.49-4.65)
p trend 0.082 0.344 0.272
MSS 1 53 1.00 55 1.00 43 1.00
2 40 0.72(0.47-1.10) 40 0.90(0.59-1.39) 34 0.67(0.42-1.06)
3 50 0.84(0.56-1.25) 58 1.14(0.78-1.67) 67 1.16(0.78-1.73)
4 73 1.37(0.95-1.99) 63 1.36(0.93-1.98) 72 1.39(0.94-2.05)
p trend 0.053 0.071 0.012
Adjusted for age, level of education, smoking habits and alcohol consumption.
*Heterogeneity analysis with p < 0.05.
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on the relationship between obesity, measured as BMI,
and risk of CRC according to beta-catenin status, whereby
the results demonstrate that obesity and physical inactivity
are associated with a higher risk of betacatenin negative
but not of betacatenin positive CRC [19]. Of note, in the
MDCS, beta-catenin overexpression has been demon-
strated to be significantly associated with favourable clini-
copathological factors and a prolonged survival [40].
As regards cyclin D1 expression, the results from the
present study demonstrate a significant association be-
tween a high height and weight and risk of cyclin D1 posi-
tive tumours in women. In men, significant associations
were seen between high BMI, WHR, waist and hip cir-
cumference and cyclin D1 positive tumours. Notably, in
order to avoid too small subgroup analyses, a dichoto-
mized variable of negative vs positive cyclin D1 expression
was used, since this cut off takes both nuclear fraction and
intensity into account and has previously shown to have
the strongest impact on survival [38]. We are not aware of
any previous studies on the influence of anthropometric
factors on CRC risk according to cyclin D1 expression. Al-
though various studies have linked the CCND1 G870A
polymorphism to increased risk of CRC, the findings re-
main controversial [22,23]. The prognostic role of cyclin
D1 has been investigated in several studies, however with
inconsistent results [48-52]. In a previous study, expres-
sion of cyclin D1 was found to be associated with a signifi-
cantly prolonged survival from CRC in men but not in
women in the MDCS [38].
Lastly, the results from the present study demonstrate a
positive relationship of all investigated anthropometric
factors except height and weight, with p53 positive tu-
mours in men, whereas in women, no associations were
found between any anthropometric factors and p53 posi-
tive CRC. In contrast, high height, in particular the top
quartile, weight and hip circumference were associated
with p53 negative tumours in women. As a cautionary re-
mark, the correlation between p53 gene mutations and
p53 positivity by immunohistochemistry is not entirely
concordant, and these analyses may therefore include
some false positive and negative cases [53]. Previous stud-
ies on anthropometric factors and risk of CRC according
to p53 expression are sparse, and with inconclusive results.
Zhang et al. reported a possible association between p53
overexpression and obesity [54], and Slattery et al. have
shown a positive relationship between western style diet
and p53 mutations, but not between obesity and p53
mutations [31].
Taken together, while it is well documented that body
size influences CRC risk, also with differences regarding
sex, location, and tumour stage, the exact biologic mech-
anisms underlying the association between obesity and
increased risk of CRC are not fully understood. A largenumber of studies have shown an increased risk of CRC in
men, but not in women, and the complex interplay be-
tween hormonal factors and tumour biology underlying
these sex differences remains to be further elucidated. Fur-
ther, our results validate previous findings demonstrating
significant associations of obesity and risk of microsatellite
unstable, but not microsatellite stable, colorectal cancer in
both sexes.
Certain methodological aspects need further attention.
The validity of the anthropometric measurements is one
aspect, as there may be a potential inter-observer vari-
ation. Recommendations for the nurses performing base-
line examinations described how participants should be
dressed, in which position the participants should be ex-
amined, and location for the estimation of waist- and
hip measurements. We therefore consider the risk of
misclassification of anthropometric measurements to be
low. In contrast, most previous studies have used self-
reported anthropometric measures.
It is also possible that participation in the MDCS was as-
sociated with body constitution, which may have lead to
potential selection bias. In a previous paper, Manjer et al.
compared BMI in the MDCS population in relation to the
background population, and found an equal distribution
of overweight/obesity [25]. Another aspect is the validity
of collected data. As anthropometric data was assessed
only at baseline, it is possible that some individuals have
gained and some have lost weight. Such a misclassification
is likely to lead to an attenuation of risks and, if anything,
observed risks may be underestimated.Conclusions
The results from this large prospective cohort study dem-
onstrate that obesity, measured by several anthropometric
factors, is differently associated with beta-catenin alter-
ations, expression of cyclin D1 and p53, and MSI screen-
ing status of colorectal tumours in men and women.
While not allowing for any firm conclusions to be drawn,
these findings further support that the influence of lifestyle
factors on various pathways of colorectal carcinogenesis
differs between sexes. Further study on this topic is en-
couraged in order to enable development of novel strat-
egies for screening and prevention of colorectal cancer.
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